In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
Andrei A Pochtovyi, Daria D Kustova, Andrei E Siniavin, Inna V Dolzhikova, Elena V Shidlovskaya, Olga G Shpakova, Lyudmila A Vasilchenko, Arina A Glavatskaya, Nadezhda A Kuznetsova, Anna A Iliukhina, Artem Y Shelkov, Olesia M Grinkevich, Andrei G Komarov, Denis Y Logunov, Vladimir A Gushchin, Alexander L Gintsburg
Vaccines, doi:10.3390/vaccines11101533
The spread of COVID-19 continues, expressed by periodic wave-like increases in morbidity and mortality. The reason for the periodic increases in morbidity is the emergence and spread of novel genetic variants of SARS-CoV-2. A decrease in the efficacy of monoclonal antibodies (mAbs) has been reported, especially against Omicron subvariants. There have been reports of a decrease in the efficacy of specific antiviral drugs as a result of mutations in the genes of non-structural proteins. This indicates the urgent need for practical healthcare to constantly monitor pathogen variability and its effect on the efficacy of preventive and therapeutic drugs. As part of this study, we report the results of the continuous monitoring of COVID-19 in Moscow using genetic and virological methods. As a result of this monitoring, we determined the dominant genetic variants and identified the variants that are most widespread, not only in Moscow, but also in other countries. A collection of viruses from more than 500 SARS-CoV-2 isolates has been obtained and characterized. The genetic lines XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, representing the greatest concern, were identified among the dominant variants. We studied the in vitro efficacy of mAbs Tixagevimab + Cilgavimab (Evusheld), Sotrovimab, Regdanvimab, Casirivimab + Imdevimab (Ronapreve), and Bebtelovimab, as well as the specific antiviral drugs Remdesivir, Molnupiravir, and Nirmatrelvir, against these genetic lines. At the current stage of the COVID-19 pandemic, the use of mAbs developed against early SARS-CoV-2 variants has little prospect. Specific antiviral drugs retain their activity, but further monitoring is needed to assess the risk of their efficacy being reduced and adjust recommendations for their use.
Conflicts of Interest: The authors declare no conflict of interest.
References
Akimkin, Popova, Khafizov, Dubodelov, Ugleva et al., COVID-19: Evolution of the Pandemic in Russia. Report II: Dynamics of the Circulation of SARS-CoV-2 Genetic Variants, J. Mikrobiol. Epidemiol. Immunobiol,
doi:10.36233/0372-9311-295Baden, El Sahly, Essink, Kotloff, Frey et al., Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, N. Engl. J. Med,
doi:10.1056/NEJMoa2035389Dubey, Choudhary, Kumar, Tomar, Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications, Curr. Microbiol,
doi:10.1007/s00284-021-02724-1Focosi, Maggi, Mcconnell, Casadevall, Very Low Levels of Remdesivir Resistance in SARS-COV-2 Genomes after 18 Months of Massive Usage during the COVID19 Pandemic: A GISAID Exploratory Analysis, Antivir. Res,
doi:10.1016/j.antiviral.2022.105247Fong, Rockett, Agius, Chandra, Johnson-Mckinnon et al., In Silico Detection of Drug Resistance Conferring Mutations in Subpopulations of SARS-CoV-2 Genomes, BMC Infect. Dis,
doi:10.1186/s12879-023-08236-6Godkov, Ogarkova, Gushchin, Kleymenov, Mazunina et al., Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level, Vaccines,
doi:10.3390/vaccines11010090Greasley, Noell, Plotnikova, Ferre, Liu et al., Structural Basis for the in Vitro Efficacy of Nirmatrelvir against SARS-CoV-2 Variants, J. Biol. Chem,
doi:10.1016/j.jbc.2022.101972Gushchin, Pochtovyi, Kustova, Ogarkova, Tarnovetskii et al., Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis, Int. J. Mol. Sci,
doi:10.3390/ijms232314670Imai, Ito, Kiso, Yamayoshi, Uraki et al., Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB, N. Engl. J. Med,
doi:10.1056/NEJMc2214302Jochmans, Liu, Donckers, Stoycheva, Boland et al., The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance to Nirmatrelvir, mBio,
doi:10.1128/mbio.02815-22Klink, Safina, Nabieva, Shvyrev, Garushyants et al., The Rise and Spread of the SARS-CoV-2 AY.122 Lineage in Russia, Virus Evol,
doi:10.1093/ve/veac017Kurhade, Zou, Xia, Liu, Chang et al., Low Neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by Parental mRNA Vaccine or a BA.5 Bivalent Booster, Nat. Med,
doi:10.1038/s41591-022-02162-xLan, Ge, Yu, Shan, Zhou et al., Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor, Nature,
doi:10.1038/s41586-020-2180-5Lau, Cheng, Leung, Lee, Hachim et al., Real-World COVID-19 Vaccine Effectiveness against the Omicron BA.2 Variant in a SARS-CoV-2 Infection-Naive Population, Nat. Med,
doi:10.1038/s41591-023-02219-5Logunov, Dolzhikova, Shcheblyakov, Tukhvatulin, Zubkova et al., Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia, Lancet,
doi:10.1016/S0140-6736(21)00234-8Miteva, Kitanova, Batselova, Lazova, Chervenkov et al., The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice, Vaccines,
doi:10.3390/vaccines11071181Moeller, Passow, Harki, Aihara, SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3 -Deoxy-3 ,4 -Didehydro-Cytidine Nucleotide from RNA, Viruses,
doi:10.3390/v14081790Pinto, Park, Beltramello, Walls, Tortorici et al., Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody, Nature,
doi:10.1038/s41586-020-2349-yPlanas, Bruel, Staropoli, Guivel-Benhassine, Porrot et al., Resistance of Omicron Subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to Neutralizing Antibodies, Nat. Commun,
doi:10.1038/s41467-023-36561-6Polack, Thomas, Kitchin, Absalon, Gurtman et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N. Engl. J. Med,
doi:10.1056/NEJMoa2034577Rognes, Flouri, Nichols, Quince, Mahé et al., A Versatile Open Source Tool for Metagenomics, PeerJ,
doi:10.7717/peerj.2584Shah, Woo, Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies, Front. Immunol,
doi:10.3389/fimmu.2021.830527Siniavin, Streltsova, Nikiforova, Kudryavtsev, Grinkina et al., Snake Venom Phospholipase A2s Exhibit Strong Virucidal Activity against SARS-CoV-2 and Inhibit the Viral Spike Glycoprotein Interaction with ACE2, Cell. Mol. Life Sci,
doi:10.1007/s00018-021-03985-6Stevens, Pruijssers, Lee, Gordon, Tchesnokov et al., Mutations in the SARS-CoV-2 RNA-Dependent RNA Polymerase Confer Resistance to Remdesivir by Distinct Mechanisms, Sci. Transl. Med,
doi:10.1126/scitranslmed.abo0718Uraki, Ito, Kiso, Yamayoshi, Iwatsuki-Horimoto et al., Antiviral and Bivalent Vaccine Efficacy against an Omicron XBB.1.5 Isolate, Lancet Infect. Dis,
doi:10.1016/S1473-3099(23)00070-1Voysey, Clemens, Madhi, Weckx, Folegatti et al., Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK, Lancet,
doi:10.1016/S0140-6736(20)32661-1Xie, Edwards, Adam, Leung, Tsang et al., Resurgence of Omicron BA.2 in SARS-CoV-2 Infection-Naive Hong Kong, Nat. Commun,
doi:10.1038/s41467-023-38201-5Yamasoba, Uriu, Plianchaisuk, Kosugi, Pan et al., Virological Characteristics of the SARS-CoV-2 Omicron XBB.1.16 Variant, Lancet Infect. Dis,
doi:10.1016/S1473-3099(23)00278-5Yazawa, Yamazaki, Saga, Itamochi, Inasaki et al., Evaluation of SARS-CoV-2 Isolation in Cell Culture from Nasal/nasopharyngeal Swabs or Saliva Specimens of Patients with COVID-19, Sci. Rep,
doi:10.1038/s41598-023-35915-w{ 'indexed': {'date-parts': [[2023, 9, 29]], 'date-time': '2023-09-29T08:46:55Z', 'timestamp': 1695977215482},
'reference-count': 49,
'publisher': 'MDPI AG',
'issue': '10',
'license': [ { 'start': { 'date-parts': [[2023, 9, 28]],
'date-time': '2023-09-28T00:00:00Z',
'timestamp': 1695859200000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'funder': [ { 'DOI': '10.13039/501100017638',
'name': 'Ministry of Health of the Russian Federation',
'doi-asserted-by': 'publisher',
'award': ['123031400022-0']}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>The spread of COVID-19 continues, expressed by periodic wave-like increases in '
'morbidity and mortality. The reason for the periodic increases in morbidity is the emergence '
'and spread of novel genetic variants of SARS-CoV-2. A decrease in the efficacy of monoclonal '
'antibodies (mAbs) has been reported, especially against Omicron subvariants. There have been '
'reports of a decrease in the efficacy of specific antiviral drugs as a result of mutations in '
'the genes of non-structural proteins. This indicates the urgent need for practical healthcare '
'to constantly monitor pathogen variability and its effect on the efficacy of preventive and '
'therapeutic drugs. As part of this study, we report the results of the continuous monitoring '
'of COVID-19 in Moscow using genetic and virological methods. As a result of this monitoring, '
'we determined the dominant genetic variants and identified the variants that are most '
'widespread, not only in Moscow, but also in other countries. A collection of viruses from '
'more than 500 SARS-CoV-2 isolates has been obtained and characterized. The genetic lines '
'XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, representing '
'the greatest concern, were identified among the dominant variants. We studied the in vitro '
'efficacy of mAbs Tixagevimab + Cilgavimab (Evusheld), Sotrovimab, Regdanvimab, Casirivimab + '
'Imdevimab (Ronapreve), and Bebtelovimab, as well as the specific antiviral drugs Remdesivir, '
'Molnupiravir, and Nirmatrelvir, against these genetic lines. At the current stage of the '
'COVID-19 pandemic, the use of mAbs developed against early SARS-CoV-2 variants has little '
'prospect. Specific antiviral drugs retain their activity, but further monitoring is needed to '
'assess the risk of their efficacy being reduced and adjust recommendations for their '
'use.</jats:p>',
'DOI': '10.3390/vaccines11101533',
'type': 'journal-article',
'created': {'date-parts': [[2023, 9, 28]], 'date-time': '2023-09-28T05:42:12Z', 'timestamp': 1695879732000},
'page': '1533',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages '
'XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1',
'prefix': '10.3390',
'volume': '11',
'author': [ { 'ORCID': 'http://orcid.org/0000-0003-1107-9351',
'authenticated-orcid': False,
'given': 'Andrei A.',
'family': 'Pochtovyi',
'sequence': 'first',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'},
{ 'name': 'Department of Virology, Biological Faculty, Lomonosov Moscow '
'State University, 119991 Moscow, Russia'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-8382-275X',
'authenticated-orcid': False,
'given': 'Daria D.',
'family': 'Kustova',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'},
{ 'name': 'Department of Virology, Biological Faculty, Lomonosov Moscow '
'State University, 119991 Moscow, Russia'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-7576-2059',
'authenticated-orcid': False,
'given': 'Andrei E.',
'family': 'Siniavin',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'},
{ 'name': 'Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian '
'Academy of Sciences, 117997 Moscow, Russia'}]},
{ 'given': 'Inna V.',
'family': 'Dolzhikova',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'}]},
{ 'given': 'Elena V.',
'family': 'Shidlovskaya',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'}]},
{ 'given': 'Olga G.',
'family': 'Shpakova',
'sequence': 'additional',
'affiliation': [{'name': 'Moscow Healthcare Department, 127006 Moscow, Russia'}]},
{ 'given': 'Lyudmila A.',
'family': 'Vasilchenko',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'}]},
{ 'given': 'Arina A.',
'family': 'Glavatskaya',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-7399-7628',
'authenticated-orcid': False,
'given': 'Nadezhda A.',
'family': 'Kuznetsova',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'}]},
{ 'given': 'Anna A.',
'family': 'Iliukhina',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'}]},
{ 'given': 'Artem Y.',
'family': 'Shelkov',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'}]},
{ 'given': 'Olesia M.',
'family': 'Grinkevich',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'}]},
{ 'given': 'Andrei G.',
'family': 'Komarov',
'sequence': 'additional',
'affiliation': [{'name': 'Moscow Healthcare Department, 127006 Moscow, Russia'}]},
{ 'given': 'Denis Y.',
'family': 'Logunov',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'}]},
{ 'given': 'Vladimir A.',
'family': 'Gushchin',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'},
{ 'name': 'Department of Virology, Biological Faculty, Lomonosov Moscow '
'State University, 119991 Moscow, Russia'}]},
{ 'given': 'Alexander L.',
'family': 'Gintsburg',
'sequence': 'additional',
'affiliation': [ { 'name': 'Federal State Budget Institution “National Research Centre for '
'Epidemiology and Microbiology Named after Honorary Academician '
'N. F. Gamaleya” of the Ministry of Health of the Russian '
'Federation, 123098 Moscow, Russia'},
{ 'name': 'Department of Infectiology and Virology, Federal State '
'Autonomous Educational Institution of Higher Education I.M. '
'Sechenov, First Moscow State Medical University of the Ministry '
'of Health of the Russian Federation (Sechenov University), '
'119435 Moscow, Russia'}]}],
'member': '1968',
'published-online': {'date-parts': [[2023, 9, 28]]},
'reference': [ { 'key': 'ref_1',
'unstructured': '(2023, August 01). WHO Coronavirus (COVID-19). Available online: '
'https://covid19.who.int/.'},
{ 'key': 'ref_2',
'doi-asserted-by': 'crossref',
'first-page': '2603',
'DOI': '10.1056/NEJMoa2034577',
'article-title': 'Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine',
'volume': '383',
'author': 'Polack',
'year': '2020',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': 'ref_3',
'doi-asserted-by': 'crossref',
'first-page': '403',
'DOI': '10.1056/NEJMoa2035389',
'article-title': 'Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine',
'volume': '384',
'author': 'Baden',
'year': '2021',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': 'ref_4',
'doi-asserted-by': 'crossref',
'first-page': '671',
'DOI': '10.1016/S0140-6736(21)00234-8',
'article-title': 'Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous '
'Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised '
'Controlled Phase 3 Trial in Russia',
'volume': '397',
'author': 'Logunov',
'year': '2021',
'journal-title': 'Lancet'},
{ 'key': 'ref_5',
'doi-asserted-by': 'crossref',
'first-page': '99',
'DOI': '10.1016/S0140-6736(20)32661-1',
'article-title': 'Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against '
'SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in '
'Brazil, South Africa, and the UK',
'volume': '397',
'author': 'Voysey',
'year': '2021',
'journal-title': 'Lancet'},
{ 'key': 'ref_6',
'unstructured': 'European Medicines Agency (2023, August 01). COVID-19 Medicines. '
'Available online: '
'https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines.'},
{ 'key': 'ref_7',
'unstructured': '(2023, August 01). Emergency Use Authorization (EUA) for the Treatment '
'of COVID-19. Available online: '
'https://www.covid19.lilly.com/bebtelovimab.'},
{ 'key': 'ref_8',
'doi-asserted-by': 'crossref',
'unstructured': 'Dubey, A., Choudhary, S., Kumar, P., and Tomar, S. (2022). Emerging '
'SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. '
'Curr. Microbiol., 79.',
'DOI': '10.1007/s00284-021-02724-1'},
{ 'key': 'ref_9',
'doi-asserted-by': 'crossref',
'first-page': '348',
'DOI': '10.1038/s41591-023-02219-5',
'article-title': 'Real-World COVID-19 Vaccine Effectiveness against the Omicron BA.2 '
'Variant in a SARS-CoV-2 Infection-Naive Population',
'volume': '29',
'author': 'Lau',
'year': '2023',
'journal-title': 'Nat. Med.'},
{ 'key': 'ref_10',
'doi-asserted-by': 'crossref',
'unstructured': 'Godkov, M.A., Ogarkova, D.A., Gushchin, V.A., Kleymenov, D.A., Mazunina, '
'E.P., Bykonia, E.N., Pochtovyi, A.A., Shustov, V.V., Shcheblyakov, D.V., '
'and Komarov, A.G. (2022). Revaccination in Age-Risk Groups with Sputnik '
'V Is Immunologically Effective and Depends on the Initial Neutralizing '
'SARS-CoV-2 IgG Antibodies Level. Vaccines, 11.',
'DOI': '10.3390/vaccines11010090'},
{ 'key': 'ref_11',
'doi-asserted-by': 'crossref',
'unstructured': 'Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., '
'Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G.V., '
'and Tomov, L. (2023). The End or a New Era of Development of SARS-CoV-2 '
'Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical '
'Efficacy of the Most Commonly Used Vaccines in Clinical Practice. '
'Vaccines, 11.',
'DOI': '10.3390/vaccines11071181'},
{ 'key': 'ref_12',
'doi-asserted-by': 'crossref',
'first-page': '344',
'DOI': '10.1038/s41591-022-02162-x',
'article-title': 'Low Neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by '
'Parental mRNA Vaccine or a BA.5 Bivalent Booster',
'volume': '29',
'author': 'Kurhade',
'year': '2023',
'journal-title': 'Nat. Med.'},
{ 'key': 'ref_13',
'doi-asserted-by': 'crossref',
'first-page': '592',
'DOI': '10.1038/s41586-023-06487-6',
'article-title': 'Neutralization, Effector Function and Immune Imprinting of Omicron '
'Variants',
'volume': '621',
'author': 'Addetia',
'year': '2023',
'journal-title': 'Nature'},
{ 'key': 'ref_14',
'doi-asserted-by': 'crossref',
'first-page': '8893',
'DOI': '10.1038/s41598-023-35915-w',
'article-title': 'Evaluation of SARS-CoV-2 Isolation in Cell Culture from '
'Nasal/nasopharyngeal Swabs or Saliva Specimens of Patients with '
'COVID-19',
'volume': '13',
'author': 'Yazawa',
'year': '2023',
'journal-title': 'Sci. Rep.'},
{ 'key': 'ref_15',
'doi-asserted-by': 'crossref',
'first-page': '493',
'DOI': '10.1093/oxfordjournals.aje.a118408',
'article-title': 'A Simple Method of estimating fifty per cent endpoints',
'volume': '27',
'author': 'Reed',
'year': '1938',
'journal-title': 'Am. J. Epidemiol.'},
{ 'key': 'ref_16',
'doi-asserted-by': 'crossref',
'unstructured': 'Gushchin, V.A., Pochtovyi, A.A., Kustova, D.D., Ogarkova, D.A., '
'Tarnovetskii, I.Y., Belyaeva, E.D., Divisenko, E.V., Vasilchenko, L.A., '
'Shidlovskaya, E.V., and Kuznetsova, N.A. (2022). Dynamics of SARS-CoV-2 '
'Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis. '
'Int. J. Mol. Sci., 23.',
'DOI': '10.3390/ijms232314670'},
{ 'key': 'ref_17',
'doi-asserted-by': 'crossref',
'first-page': 'veac017',
'DOI': '10.1093/ve/veac017',
'article-title': 'The Rise and Spread of the SARS-CoV-2 AY.122 Lineage in Russia',
'volume': '8',
'author': 'Klink',
'year': '2022',
'journal-title': 'Virus Evol.'},
{ 'key': 'ref_18',
'doi-asserted-by': 'crossref',
'first-page': '10',
'DOI': '10.14806/ej.17.1.200',
'article-title': 'Cutadapt Removes Adapter Sequences from High- Throughput Sequencing '
'Reads',
'volume': '17',
'author': 'Martin',
'year': '2011',
'journal-title': 'EMBnet. J.'},
{ 'key': 'ref_19',
'doi-asserted-by': 'crossref',
'first-page': 'e2584',
'DOI': '10.7717/peerj.2584',
'article-title': 'VSEARCH: A Versatile Open Source Tool for Metagenomics',
'volume': '2016',
'author': 'Rognes',
'year': '2016',
'journal-title': 'PeerJ'},
{ 'key': 'ref_20',
'doi-asserted-by': 'crossref',
'first-page': '1754',
'DOI': '10.1093/bioinformatics/btp324',
'article-title': 'Fast and Accurate Short Read Alignment with Burrows-Wheeler Transform',
'volume': '25',
'author': 'Li',
'year': '2009',
'journal-title': 'Bioinformatics'},
{ 'key': 'ref_21',
'unstructured': 'Garrison, E., and Marth, G. (2012). Haplotype-Based Variant Detection '
'from Short-Read Sequencing. arXiv.'},
{ 'key': 'ref_22',
'doi-asserted-by': 'crossref',
'first-page': '2078',
'DOI': '10.1093/bioinformatics/btp352',
'article-title': 'The Sequence Alignment/Map Format and SAMtools',
'volume': '25',
'author': 'Li',
'year': '2009',
'journal-title': 'Bioinformatics'},
{ 'key': 'ref_23',
'doi-asserted-by': 'crossref',
'first-page': '841',
'DOI': '10.1093/bioinformatics/btq033',
'article-title': 'BEDTools: A Flexible Suite of Utilities for Comparing Genomic Features',
'volume': '26',
'author': 'Quinlan',
'year': '2010',
'journal-title': 'Bioinformatics'},
{ 'key': 'ref_24',
'unstructured': '(2023, August 01). ARTIC: A Bioinformatics Pipeline for Working with '
'Virus Sequencing Data Sequenced with Nanopore. Available online: '
'https://artic.network/.'},
{ 'key': 'ref_25',
'unstructured': 'Official Website U.S. Food & Drug (2023, August 01). Coronavirus '
'(COVID-19). Drugs, Available online: '
'https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs.'},
{ 'key': 'ref_26',
'unstructured': '(2023, August 01). Temporary Guidelines «Prevention, Diagnosis and '
'Treatment of New Coronavirus Infection (COVID-19)», Version 17, '
'Available online: '
'https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0_COVID-19_V17.pdf.'},
{ 'key': 'ref_27',
'doi-asserted-by': 'crossref',
'first-page': '7777',
'DOI': '10.1007/s00018-021-03985-6',
'article-title': 'Snake Venom Phospholipase A2s Exhibit Strong Virucidal Activity against '
'SARS-CoV-2 and Inhibit the Viral Spike Glycoprotein Interaction with '
'ACE2',
'volume': '78',
'author': 'Siniavin',
'year': '2021',
'journal-title': 'Cell. Mol. Life Sci.'},
{ 'key': 'ref_28',
'doi-asserted-by': 'crossref',
'first-page': '89',
'DOI': '10.1056/NEJMc2214302',
'article-title': 'Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB',
'volume': '388',
'author': 'Imai',
'year': '2023',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': 'ref_29',
'doi-asserted-by': 'crossref',
'first-page': '22',
'DOI': '10.1016/S1473-3099(22)00733-2',
'article-title': 'Omicron Sublineage BQ.1.1 Resistance to Monoclonal Antibodies',
'volume': '23',
'author': 'Arora',
'year': '2023',
'journal-title': 'Lancet Infect. Dis.'},
{ 'key': 'ref_30',
'doi-asserted-by': 'crossref',
'first-page': '569353',
'DOI': '10.3389/fpubh.2020.569353',
'article-title': 'With Corona Outbreak: Nature Started Hitting the Reset Button Globally',
'volume': '8',
'author': 'Kumar',
'year': '2020',
'journal-title': 'Front. Public Health'},
{ 'key': 'ref_31',
'doi-asserted-by': 'crossref',
'first-page': '101512',
'DOI': '10.1016/j.frl.2020.101512',
'article-title': 'COVID-19 and Finance: Agendas for Future Research',
'volume': '35',
'author': 'Goodell',
'year': '2020',
'journal-title': 'Financ. Res. Lett.'},
{ 'key': 'ref_32',
'doi-asserted-by': 'crossref',
'first-page': '381',
'DOI': '10.36233/0372-9311-295',
'article-title': 'COVID-19: Evolution of the Pandemic in Russia. Report II: Dynamics of '
'the Circulation of SARS-CoV-2 Genetic Variants',
'volume': '99',
'author': 'Akimkin',
'year': '2022',
'journal-title': 'J. Mikrobiol. Epidemiol. Immunobiol.'},
{ 'key': 'ref_33',
'doi-asserted-by': 'crossref',
'first-page': '2422',
'DOI': '10.1038/s41467-023-38201-5',
'article-title': 'Resurgence of Omicron BA.2 in SARS-CoV-2 Infection-Naive Hong Kong',
'volume': '14',
'author': 'Xie',
'year': '2023',
'journal-title': 'Nat. Commun.'},
{ 'key': 'ref_34',
'doi-asserted-by': 'crossref',
'first-page': '655',
'DOI': '10.1016/S1473-3099(23)00278-5',
'article-title': 'Virological Characteristics of the SARS-CoV-2 Omicron XBB.1.16 Variant',
'volume': '23',
'author': 'Yamasoba',
'year': '2023',
'journal-title': 'Lancet Infect. Dis.'},
{ 'key': 'ref_35',
'doi-asserted-by': 'crossref',
'first-page': '824',
'DOI': '10.1038/s41467-023-36561-6',
'article-title': 'Resistance of Omicron Subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to '
'Neutralizing Antibodies',
'volume': '14',
'author': 'Planas',
'year': '2023',
'journal-title': 'Nat. Commun.'},
{ 'key': 'ref_36',
'doi-asserted-by': 'crossref',
'unstructured': 'Focosi, D., Spezia, P.G., Capria, A.-L., Gueli, F., McConnell, S., '
'Novazzi, F., and Pistello, M. (2023). Rise of the BQ.1.1.37 SARS-CoV-2 '
'Sublineage, Italy. Diagnostics, 13.',
'DOI': '10.3390/diagnostics13051000'},
{ 'key': 'ref_37',
'doi-asserted-by': 'crossref',
'first-page': '603',
'DOI': '10.1038/s41586-022-05053-w',
'article-title': 'Antibody Evasion by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4 and '
'BA.5',
'volume': '608',
'author': 'Wang',
'year': '2022',
'journal-title': 'Nature'},
{ 'key': 'ref_38',
'doi-asserted-by': 'crossref',
'first-page': '830527',
'DOI': '10.3389/fimmu.2021.830527',
'article-title': 'Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding '
'to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies',
'volume': '12',
'author': 'Shah',
'year': '2022',
'journal-title': 'Front. Immunol.'},
{ 'key': 'ref_39',
'doi-asserted-by': 'crossref',
'first-page': '215',
'DOI': '10.1038/s41586-020-2180-5',
'article-title': 'Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the '
'ACE2 Receptor',
'volume': '581',
'author': 'Lan',
'year': '2020',
'journal-title': 'Nature'},
{ 'key': 'ref_40',
'doi-asserted-by': 'crossref',
'first-page': '290',
'DOI': '10.1038/s41586-020-2349-y',
'article-title': 'Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV '
'Antibody',
'volume': '583',
'author': 'Pinto',
'year': '2020',
'journal-title': 'Nature'},
{ 'key': 'ref_41',
'doi-asserted-by': 'crossref',
'first-page': '558',
'DOI': '10.1038/s41586-022-05514-2',
'article-title': 'Multiple Pathways for SARS-CoV-2 Resistance to Nirmatrelvir',
'volume': '613',
'author': 'Iketani',
'year': '2023',
'journal-title': 'Nature'},
{ 'key': 'ref_42',
'doi-asserted-by': 'crossref',
'unstructured': 'Jochmans, D., Liu, C., Donckers, K., Stoycheva, A., Boland, S., Stevens, '
'S.K., De Vita, C., Vanmechelen, B., Maes, P., and Trüeb, B. (2023). The '
'Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected '
'by a Protease Inhibitor In Vitro and Confer Resistance to Nirmatrelvir. '
'mBio, 14.',
'DOI': '10.1128/mbio.02815-22'},
{ 'key': 'ref_43',
'doi-asserted-by': 'crossref',
'unstructured': 'Greasley, S.E., Noell, S., Plotnikova, O., Ferre, R., Liu, W., Bolanos, '
'B., Fennell, K., Nicki, J., Craig, T., and Zhu, Y. (2022). Structural '
'Basis for the in Vitro Efficacy of Nirmatrelvir against SARS-CoV-2 '
'Variants. J. Biol. Chem., 298.',
'DOI': '10.1101/2022.01.17.476556'},
{ 'key': 'ref_44',
'unstructured': 'Official Website Chemical & Engineering News (2023, August 01). Pfizer '
'Unveils Its Oral SARS-CoV-2 Inhibitor. Available online: '
'https://cen.acs.org/acs-news/acs-meeting-news/Pfizer-unveils-oral-SARS-CoV/99/i13.'},
{ 'key': 'ref_45',
'doi-asserted-by': 'crossref',
'unstructured': 'Moeller, N.H., Passow, K.T., Harki, D.A., and Aihara, H. (2022). '
'SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral '
'3′-Deoxy-3′,4′-Didehydro-Cytidine Nucleotide from RNA. Viruses, 14.',
'DOI': '10.3390/v14081790'},
{ 'key': 'ref_46',
'doi-asserted-by': 'crossref',
'first-page': '105247',
'DOI': '10.1016/j.antiviral.2022.105247',
'article-title': 'Very Low Levels of Remdesivir Resistance in SARS-COV-2 Genomes after 18 '
'Months of Massive Usage during the COVID19 Pandemic: A GISAID '
'Exploratory Analysis',
'volume': '198',
'author': 'Focosi',
'year': '2022',
'journal-title': 'Antivir. Res.'},
{ 'key': 'ref_47',
'doi-asserted-by': 'crossref',
'unstructured': 'Fong, W., Rockett, R.J., Agius, J.E., Chandra, S., Johnson-Mckinnon, J., '
'Sim, E., Lam, C., Arnott, A., Gall, M., and Draper, J. (2023). SABRes: '
'In Silico Detection of Drug Resistance Conferring Mutations in '
'Subpopulations of SARS-CoV-2 Genomes. BMC Infect. Dis., 23.',
'DOI': '10.1186/s12879-023-08236-6'},
{ 'key': 'ref_48',
'doi-asserted-by': 'crossref',
'first-page': 'eabo0718',
'DOI': '10.1126/scitranslmed.abo0718',
'article-title': 'Mutations in the SARS-CoV-2 RNA-Dependent RNA Polymerase Confer '
'Resistance to Remdesivir by Distinct Mechanisms',
'volume': '14',
'author': 'Stevens',
'year': '2022',
'journal-title': 'Sci. Transl. Med.'},
{ 'key': 'ref_49',
'doi-asserted-by': 'crossref',
'first-page': '402',
'DOI': '10.1016/S1473-3099(23)00070-1',
'article-title': 'Antiviral and Bivalent Vaccine Efficacy against an Omicron XBB.1.5 '
'Isolate',
'volume': '23',
'author': 'Uraki',
'year': '2023',
'journal-title': 'Lancet Infect. Dis.'}],
'container-title': 'Vaccines',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.mdpi.com/2076-393X/11/10/1533/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 9, 28]],
'date-time': '2023-09-28T07:15:20Z',
'timestamp': 1695885320000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.mdpi.com/2076-393X/11/10/1533'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 9, 28]]},
'references-count': 49,
'journal-issue': {'issue': '10', 'published-online': {'date-parts': [[2023, 10]]}},
'alternative-id': ['vaccines11101533'],
'URL': 'http://dx.doi.org/10.3390/vaccines11101533',
'relation': {},
'ISSN': ['2076-393X'],
'subject': [ 'Pharmacology (medical)', 'Infectious Diseases', 'Drug Discovery', 'Pharmacology',
'Immunology'],
'container-title-short': 'Vaccines',
'published': {'date-parts': [[2023, 9, 28]]}}
